Residual Variants May Predict Relapse, Death in AML
Residual variants are associated with a higher risk of relapse and death among AML patients undergoing HSCT in first remission, a study suggests.
Residual variants are associated with a higher risk of relapse and death among AML patients undergoing HSCT in first remission, a study suggests.
Adolescent and young adult patients diagnosed with cancer during pregnancy have a higher risk of adverse birth outcomes, a study suggests.
Several factors influenced the likelihood of COVID-19 vaccination among patients with cancer who already had COVID-19, a new study suggests.
Infections are common among patients with relapsed/refractory multiple myeloma treated with bispecific antibodies, a study suggests.
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
An FDA panel voted in favor of approving polatuzumab vedotin in combination with R-CHP for previously untreated DLBCL.
What are some of the most important factors affecting outcomes in patients with multiple myeloma?
COVID-19 vaccination may reduce the risk of COVID-19 sequelae in patients with cancer, according to researchers.
In the US, AYAs with cancer face high economic and human costs throughout their lifetime.
A dedicated outpatient care clinic at an established cancer center decreased the time from febrile neutropenia onset to treatment.